Alona Zer

8.7k total citations · 1 hit paper
127 papers, 3.2k citations indexed

About

Alona Zer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Alona Zer has authored 127 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Pulmonary and Respiratory Medicine, 84 papers in Oncology and 24 papers in Cancer Research. Recurrent topics in Alona Zer's work include Lung Cancer Treatments and Mutations (59 papers), Cancer Immunotherapy and Biomarkers (32 papers) and Lung Cancer Research Studies (31 papers). Alona Zer is often cited by papers focused on Lung Cancer Treatments and Mutations (59 papers), Cancer Immunotherapy and Biomarkers (32 papers) and Lung Cancer Research Studies (31 papers). Alona Zer collaborates with scholars based in Israel, United States and Canada. Alona Zer's co-authors include Elizabeth Dudnik, Federico Cappuzzo, Alessandro Morabito, Hans‐Georg Kopp, Tarek Mekhail, Howard West, Niels Reinmuth, Venice Archer, Marcin Kowanetz and Michael McCleod and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Alona Zer

118 papers receiving 3.2k citations

Hit Papers

Atezolizumab in combination with carboplatin plus nab-pac... 2019 2026 2021 2023 2019 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alona Zer Israel 27 2.4k 1.8k 380 342 332 127 3.2k
Renato Martins United States 24 2.6k 1.1× 1.7k 1.0× 811 2.1× 436 1.3× 445 1.3× 81 4.0k
Alan H. Bryce United States 26 1.0k 0.4× 1.3k 0.7× 642 1.7× 199 0.6× 545 1.6× 167 2.5k
Alessandra Bearz Italy 31 2.5k 1.0× 3.1k 1.7× 772 2.0× 137 0.4× 459 1.4× 176 4.4k
Michael S. Rabin United States 27 1.9k 0.8× 2.3k 1.3× 654 1.7× 159 0.5× 419 1.3× 86 3.2k
Nicolas Vénissac France 25 1.2k 0.5× 1.5k 0.9× 408 1.1× 126 0.4× 615 1.9× 105 2.8k
Marta M. Gilson United States 19 2.3k 1.0× 779 0.4× 404 1.1× 1.1k 3.2× 262 0.8× 33 3.5k
Ben Tran Australia 14 2.7k 1.1× 994 0.6× 405 1.1× 517 1.5× 1.1k 3.2× 61 4.0k
Gilberto Lopes United States 21 1.2k 0.5× 874 0.5× 259 0.7× 126 0.4× 284 0.9× 108 1.9k
P. Fournel France 26 2.4k 1.0× 3.4k 1.9× 455 1.2× 161 0.5× 305 0.9× 159 4.6k
H. Léna France 20 1.2k 0.5× 1.7k 1.0× 300 0.8× 151 0.4× 234 0.7× 95 2.3k

Countries citing papers authored by Alona Zer

Since Specialization
Citations

This map shows the geographic impact of Alona Zer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alona Zer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alona Zer more than expected).

Fields of papers citing papers by Alona Zer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alona Zer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alona Zer. The network helps show where Alona Zer may publish in the future.

Co-authorship network of co-authors of Alona Zer

This figure shows the co-authorship network connecting the top 25 collaborators of Alona Zer. A scholar is included among the top collaborators of Alona Zer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alona Zer. Alona Zer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tschernichovsky, Roi, Daniel A. Goldstein, Elizabeth Dudnik, et al.. (2023). Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non‐small cell lung cancer: A large real‐world cohort and review of the literature. Thoracic Cancer. 14(17). 1589–1596. 3 indexed citations
2.
3.
Moskovitz, Mor, Sivan Shamai, Barliz Waissengrin, et al.. (2023). P2.07-09 Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO?. Journal of Thoracic Oncology. 18(11). S327–S327. 1 indexed citations
4.
Leader, Avi, Erez Batat, Tzippy Shochat, et al.. (2023). Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study. The Oncologist. 28(6). e391–e396. 4 indexed citations
5.
Rotem, Ofer, Alona Zer, Einat Beery, et al.. (2023). Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy. Biomedicines. 11(6). 1730–1730. 3 indexed citations
6.
Cho, Byoung Chul, Melissa L. Johnson, Jair Bar, et al.. (2023). 655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC). Annals of Oncology. 34. S460–S461. 5 indexed citations
7.
Shimony, Shai, Tzippy Shochat, Galia Spectre, et al.. (2021). Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. Journal of Thrombosis and Haemostasis. 19(5). 1250–1258. 54 indexed citations
8.
Shepshelovich, Daniel, Noam Barda, Hadar Goldvaser, et al.. (2021). Incidence of lung cancer following pneumonia in smokers: a population-based study. QJM. 115(5). 287–291. 4 indexed citations
9.
Domachevsky, Liran, David Groshar, Elizabeth Dudnik, et al.. (2020). Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non‐small‐cell lung cancer. Asia-Pacific Journal of Clinical Oncology. 17(2). e125–e131. 4 indexed citations
10.
Rennert, Gad, Maya Gottfried, Hedy S. Rennert, et al.. (2020). Long term follow-up of EGFR mutated NSCLC cases. Translational Oncology. 14(1). 100934–100934. 8 indexed citations
11.
Moore, Assaf, Mordechai R. Kramer, Dror Rosengarten, et al.. (2020). Stereotactic body radiation therapy (SBRT) for the treatment of primary lung cancer in recipients of lung transplant. Radiology and Oncology. 54(2). 227–232. 1 indexed citations
12.
Rotem, Ofer, et al.. (2020). Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer. 143. 40–46. 37 indexed citations
13.
Nishio, Makoto, Nir Peled, Alona Zer, et al.. (2020). 1313P Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC. Annals of Oncology. 31. S848–S849. 11 indexed citations
14.
Peled, Nir, et al.. (2019). Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience.. PubMed. 21(6). 394–398. 1 indexed citations
15.
Dudnik, Elizabeth, Jair Bar, Mor Moskovitz, et al.. (2019). P2.06-14 BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPi and PARPi. Journal of Thoracic Oncology. 14(10). S760–S760. 1 indexed citations
16.
Dudnik, Elizabeth, Mor Moskovitz, Abed Agbarya, et al.. (2019). OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data. Journal of Thoracic Oncology. 14(10). S235–S236. 6 indexed citations
17.
West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937. 1137 indexed citations breakdown →
18.
Bugano, Diogo Diniz Gomes, Kenneth R. Hess, Denis L. Jardim, et al.. (2017). Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. Clinical Cancer Research. 23(15). 4020–4026. 17 indexed citations
19.
Zer, Alona, Mor Moskovitz, David Hwang, et al.. (2017). OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. Journal of Thoracic Oncology. 12(1). S326–S327. 1 indexed citations
20.
Zer, Alona, Shulamit Rizel, Rony Braunstein, et al.. (2012). Tailoring Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Historical Prospective Study. Chemotherapy. 58(2). 95–101. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Renato Martins Breakdown of academic impact, for papers by Alan H. Bryce Breakdown of academic impact, for papers by Alessandra Bearz Breakdown of academic impact, for papers by Michael S. Rabin Breakdown of academic impact, for papers by Nicolas Vénissac Breakdown of academic impact, for papers by Marta M. Gilson Breakdown of academic impact, for papers by Ben Tran Breakdown of academic impact, for papers by Gilberto Lopes Breakdown of academic impact, for papers by P. Fournel Breakdown of academic impact, for papers by H. Léna
Rankless by CCL
2026